Sector News

Medtronic appoints Madan Krishnan as VP Indian Sub-continent

September 8, 2016
Life sciences

Global medical technology major Medtronic plc has appointed Madan Krishnan as Vice President for Indian sub-continent.

In this role, Krishnan will lead the Medtronic Indian sub-continent business (ISC), which includes India, Sri Lanka, Bangladeshand Nepal, Medtronic plc said in a statement.

Commenting on the development, Medtronic AsiaPacific President Bob White said: “”We see tremendous growth potential in ISC and I have full confidence in Madan’s ability to be an engaged and collaborative industry leader while caring for our employees.”

Krishnan joined Medtronic in 2011. Prior to this appointment, Krishnan was vice president of finance, AsiaPacific (APAC).

Medtronic began its operations in Indiain 1979. Headquartered in Mumbai, the company has offices at Ahmedabad, Bengaluru, Chennai, Cochin, Dhaka, Gurgaon, Hyderabad, Kolkata, New Delhi, Puneand Vadodara.

Source: Business Standard

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.